Aberdeen Group’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.8M | Sell |
456,802
-20,496
| -4% | -$1.37M | 0.04% | 331 |
|
|
2026
Q1 | $30M | Sell |
477,298
-53,065
| -10% | -$3.7M | 0.05% | 307 |
|
|
2025
Q4 | $35.2M | Buy |
530,363
+43,990
| +9% | +$2.84M | 0.05% | 281 |
|
|
2025
Q3 | $32.5M | Buy |
486,373
+180,943
| +59% | +$14.3M | 0.05% | 301 |
|
|
2025
Q2 | $26.5M | Sell |
305,430
-55,294
| -15% | -$4.33M | 0.05% | 334 |
|
|
2025
Q1 | $24.3M | Buy |
360,724
+13,173
| +4% | +$1.07M | 0.05% | 342 |
|
|
2024
Q4 | $27.1M | Sell |
347,551
-37,095
| -10% | -$2.75M | 0.05% | 310 |
|
|
2024
Q3 | $25.8M | Buy |
384,646
+85,174
| +28% | +$6.99M | 0.05% | 330 |
|
|
2024
Q2 | $34M | Sell |
299,472
-94,153
| -24% | -$11.9M | 0.07% | 274 |
|
|
2024
Q1 | $54.6M | Buy |
393,625
+13,090
| +3% | +$1.65M | 0.11% | 202 |
|
|
2023
Q4 | $47.2M | Buy |
380,535
+66,348
| +21% | +$6.78M | 0.1% | 215 |
|
|
2023
Q3 | $29.3M | Buy |
314,187
+14,401
| +5% | +$1.62M | 0.07% | 245 |
|
|
2023
Q2 | $38.5M | Buy |
299,786
+26,646
| +10% | +$3.22M | 0.09% | 213 |
|
|
2023
Q1 | $31.7M | Buy |
273,140
+20,615
| +8% | +$2.31M | 0.08% | 251 |
|
|
2022
Q4 | $28.6M | Buy |
252,525
+18,018
| +8% | +$1.98M | 0.08% | 268 |
|
|
2022
Q3 | $18.9M | Buy |
234,507
+95,001
| +68% | +$8.05M | 0.06% | 324 |
|
|
2022
Q2 | $10.5M | Buy |
139,506
+13,354
| +11% | +$1.22M | 0.03% | 413 |
|
|
2022
Q1 | $16.3M | Sell |
126,152
-4,816
| -4% | -$527K | 0.04% | 343 |
|
|
2021
Q4 | $17.6M | Sell |
130,968
-6,528
| -5% | -$938K | 0.04% | 370 |
|
|
2021
Q3 | $18.7M | Buy |
137,496
+6,032
| +5% | +$761K | 0.04% | 363 |
|
|
2021
Q2 | $14M | Sell |
131,464
-3,296
| -2% | -$317K | 0.03% | 426 |
|
|
2021
Q1 | $12.1M | Buy |
134,760
+7,656
| +6% | +$719K | 0.03% | 450 |
|
|
2020
Q4 | $11.8M | Buy |
127,104
+10,400
| +9% | +$929K | 0.03% | 432 |
|
|
2020
Q3 | $12M | Sell |
116,704
-15,476
| -12% | -$1.62M | 0.03% | 384 |
|
|
2020
Q2 | $13.4M | Buy |
132,180
+82,460
| +166% | +$7.38M | 0.04% | 360 |
|
|
2020
Q1 | $3.35M | Buy |
49,720
+948
| +2% | +$59K | 0.01% | 597 |
|
|
2019
Q4 | $2.67M | Buy |
48,772
+500
| +1% | +$23.7K | 0.01% | 687 |
|
|
2019
Q3 | $1.8M | Buy |
48,272
+2,132
| +5% | +$82.8K | ﹤0.01% | 726 |
|
|
2019
Q2 | $1.73M | Buy |
46,140
+912
| +2% | +$28.7K | ﹤0.01% | 762 |
|
|
2019
Q1 | $1.35M | Buy |
45,228
+26,616
| +143% | +$935K | ﹤0.01% | 776 |
|
|
2018
Q4 | $549K | Buy |
+18,612
| New | +$590K | ﹤0.01% | 817 |
|
Other funds holding DXCM
Aberdeen Group's DXCM Position: Q2 2026 in Review
Aberdeen Group reduced its DexCom (DXCM) stake by 4.3% in Q2 2026, selling an estimated $1.37M and leaving 456,802 shares worth $30.8M. The position accounts for 0.04% of the portfolio, ranked #331.
Aberdeen Group first reported a position in DXCM in Q4 2018 and has held it in 31 quarters since. The position peaked at $54.6M in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Aberdeen Group held 456,802 shares of DexCom worth $30.8M as of Q2 2026.
- Aberdeen Group sold 20,496 DexCom shares in Q2 2026, an estimated $1.37M.
- DexCom made up 0.04% of Aberdeen Group's portfolio in Q2 2026, its #331 holding.
- Aberdeen Group first reported a position in DexCom in Q4 2018 and has held it in 31 quarters since.
- Aberdeen Group's DexCom position peaked at $54.6M in Q1 2024.
- 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.